Tag: GlobeNewswire

The Agency reiterated its commitment to addressing the unmet need for treatment of congenital and tumor-related hyperinsulinism and to serving these patient communities 

On track to report topline results for the Phase 3 upLIFT study in tumor HI this quarter

REDWOOD CITY, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (“HI”), today announced that following a preliminary review of detailed data from the Phase 3 sunRIZE study of ersodetug for the treatment of hypoglycemia due to congenital HI, the U.S. Food and Drug Administration (“FDA” or “Agency”) recommended a pre-BLA meeting with the Company as a precursor to submitting a BLA.

As previously reported, sunRIZE, a Phase 3, multicenter, double-blind, randomized, placebo-controlled safety and efficacy study of ersodetug for the treatment of congenital HI, demonstrated glycemic improvements, but did not meet the primary endpoint because the reductions in hypoglycemia events by finger-stick self-monitored blood glucose (SMBG) were not statistically significant compared to placebo. Although the key secondary endpoint of time in hypoglycemia by continuous glucose monitoring (CGM) was not met in the Week 24 End-of-Treatment evaluable window, consistent and clinically relevant improvements in hypoglycemia were observed for this and multiple other CGM-based hypoglycemia endpoints in both treatment arms.

At a March 2026 Type B meeting with FDA, the Agency acknowledged the challenges posed by behavioral factors in clinical trials in this patient population, including limitations associated with SMBG based measures of hypoglycemia. At the meeting, the Agency requested that the Company provide the continuous CGM data for its independent review. In June 2026, the Company submitted source and analysis datasets, and summary results from a substantial number of pre-specified, post-hoc, and sensitivity analyses.

The Agency has reviewed the data and, despite the trial’s failure to meet the prespecified primary and key secondary endpoints, as a next step, encouraged the Company to request a Type B pre-BLA meeting as a precursor to submitting a BLA for congenital HI. The Agency explicitly did not opine on the approvability of ersodetug for congenital HI and noted that any such determination would only be made as a part of an in-depth evaluation of the supporting data during a formal BLA review, as is customary during a BLA process.

In light of expected topline results this quarter from the Company’s upLIFT study in tumor HI and the potential for an additional pre-BLA meeting for that indication should the study results support a submission, the Company will evaluate its overall BLA submission strategy for potentially both programs following the announcement of upLIFT study results.

“We appreciate FDA’s thorough review of the extensive body of data generated in sunRIZE and are encouraged by the Agency’s recognition that this data will require in-depth evaluation during a formal BLA review,” said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. “We share FDA’s commitment to addressing the significant unmet needs of individuals living with rare diseases like congenital HI, where traditional drug development can present unique challenges. We believe this unusual process of preliminary review of detailed data demonstrates what can be achieved when regulators, companies, clinicians, and advocacy organizations work collaboratively to evaluate the totality of evidence for promising rare disease therapies.”

“For many people living with congenital hyperinsulinism, the threat of severe and unpredictable hypoglycemia remains a daily reality, and existing treatments are not enough,” said Julie Raskin, Chief Executive Officer of Congenital Hyperinsulinism International (CHI). “We are encouraged by the progress toward potential new therapies and grateful to the patients, families, researchers, clinicians, regulators, and biotechnology companies working together to bring better options to our community.”

The open-label extension (OLE) phase of the study is ongoing, with a continued high retention rate, equating to an ersodetug treatment duration in sunRIZE ranging from approximately nine months to well over two years. This, along with continued glycemic control and a notable reduction in the use of background standard of care therapies, potentially indicate continued glycemic and clinical benefit with ersodetug in longer-term use.

About Ersodetug 

Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances (such as IGF-2) in the setting of hyperinsulinism (HI), thereby improving hypoglycemia. Because ersodetug acts downstream from pancreatic insulin or paraneoplastic IGF-2 secretion and from entero-incretin pathways, it has the potential to be universally effective at treating refractory hypoglycemia due to any form of hyperinsulinism (HI), including congenital HI, tumor HI (insulinoma, non-islet cell tumors) or bariatric/non-bariatric gastrointestinal surgery hypoglycemia. Ersodetug for the treatment of HI is investigational. Statements about safety and efficacy have not been approved by any health authority.

About Rezolute, Inc. 

Rezolute is a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI. For more information, visit www.rezolutebio.com.

Forward-Looking Statements  

This release, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “seek,” “strive,” “try,” or future or conditional verbs such as “could,” “may,” “should,” “will,” “would,” or similar expressions. These forward-looking statements include, but are not limited to, the overall BLA process, the potential efficacy of ersodetug in treating hypoglycemia as well as our ability to complete enrollment of the upLIFT study this year and announce topline results. Our ability to predict results or our plans or strategies is inherently uncertain. Notably, despite the FDA encouraging us to request a pre-BLA meeting for congenital HI, there can be no assurance that FDA will agree with the Company that the totality of evidence from the sunRIZE program demonstrates a clinically meaningful benefit or is sufficient to support the approval for ersodetug in congenital HI. Accordingly, FDA may determine that additional clinical data, including data from a new randomized controlled trial similar to sunRIZE, are required to support approval. Should the Agency make such a determination, it would adversely impact the timing and feasibility of approval for the congenital HI indication as well as the the commercial potential for ersodetug. Actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include any other factors discussed in our filings with the SEC, including the Risk Factors contained in Rezolute’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the U.S. Securities and Exchange Commission’s website at www.sec.gov. You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. 

Contacts: 

Christen Baglaneas
Rezolute, Inc.
1411 Broadway, 16th Floor
New York, NY 10018
cbaglaneas@rezolutebio.com
508-272-6717

Carrie McKim
Rezolute, Inc.
1411 Broadway, 16th Floor
New York, NY 10018
cmkim@rezolutebio.com
336-608-9706

Tsang joins AIBotics as Strategic Advisor ahead of contemplated CEO and director appointment upon closing, as Company moves to acquire the U.S.-focused Empulser defense-technology platform

MIAMI, Oct. 05, 2026 (GLOBE NEWSWIRE) — AIBotics, Inc. (OTCID: AIBT) (“AIBotics” or the “Company”), a public company focused on AI-enabled robotics, intelligent automation and emerging technology, today announced that on October 2, 2026 it entered into an Agreement for the Exchange of Stock (the “Exchange Agreement”) with Empulser Enterprises LLC (“Empulser”), a Wyoming limited liability company founded by Patrick Tsang, and the members of Empulser. Upon closing, AIBotics will acquire 100% of the issued and outstanding membership interests of Empulser, and Empulser will become a wholly owned subsidiary of AIBotics. In connection with the transaction and the Company’s next phase of strategic growth, Tsang has joined AIBotics as a Strategic Advisor.

The agreement brings Tsang and Empulser to the center of AIBotics’ evolving public-company strategy. Empulser is being developed around the convergence of wireless power, autonomous systems, AI-enabled unmanned technologies and the infrastructure required to support more persistent autonomous operations. The proposed acquisition is intended to provide a public-market platform through which Empulser can pursue technology development, intellectual-property expansion, testing and validation, capitalization, strategic relationships and, ultimately, commercial and defense applications.

Patrick Tsang Brings a New Technology Platform to AIBotics

Tsang brings more than two decades of experience across global capital markets, public-company transactions, mergers and acquisitions, strategic investing, corporate development and emerging technology. As Strategic Advisor to AIBotics, he is expected to work with Chief Executive Officer Ben Kaplan and the Company on strategic growth, capital-markets strategy, corporate development, international partnerships and the identification of opportunities across AI, robotics, autonomous systems and related technologies.

Tsang is Chairman of Tsang Group, a fourth-generation single family office with interests across technology, real estate and natural resources. Over more than two decades, he has worked across international investment, capital formation, mergers and acquisitions, corporate development and emerging technology, building relationships across Asia, Europe, the Middle East and North America. He is also the Founder and Chief Executive Officer of Empulser, the defense and dual-use technology platform that AIBotics has agreed to acquire.

A Public-Market Track Record

Under Patrick Tsang’s leadership, an early-stage investment was made in Pulse Evolution Group in 2018, alongside a strategic advisory role. Pulse subsequently became part of FaceBank Group, which completed its merger with fuboTV in 2020, culminating in fuboTV trading on the New York Stock Exchange during the Covid period.

Empulser: Defense, Autonomy and the Infrastructure Behind Intelligent Machines

Empulser is focused on building a U.S. defense and dual-use technology platform around wireless power and autonomous systems. Its development strategy centers on technologies intended to address a fundamental challenge facing unmanned platforms: extending operational endurance while reducing dependence on manual charging and support infrastructure. Empulser’s broader vision includes wireless power transfer, autonomous aerial and ground systems, AI-enabled mission functionality and infrastructure designed to support unmanned operations across defense, government, critical-infrastructure and commercial environments.

Empulser remains in a development and commercialization phase. Future technology, product, testing, certification, customer and revenue milestones will be announced only as they are achieved and can be substantiated. AIBotics and Empulser intend to build public communications around documented execution rather than projected milestones.

Transaction Overview

Under the Exchange Agreement, AIBotics will acquire 100% of the issued and outstanding membership interests of Empulser from the Empulser Members in exchange for up to 2,200,000 shares of a newly designated Series C Preferred Stock having an aggregate stated value of up to $22.0 million. The Certificate of Designation provides for an original issue price of $10.00 per share. Of the total acquisition consideration, 220,000 shares, representing 10%, are allocated to the closing and 198,000, representing 9%, shares are allocated to each of ten separate earn-out milestones.

The earn-out period begins at closing and continues for 36 months. The milestones cover specified patent filings and issuances, product demonstration and flight testing, acceptance into a formal test, evaluation or pilot program, and achievement of $500,000 in cumulative recognized revenue. Shares tied to a milestone are earned only if that milestone is achieved during the earn-out period; unearned milestone shares will cease to be issuable or will be forfeited and cancelled, as applicable under the Exchange Agreement.

The Series C Preferred Stock pays no dividends and generally has no voting rights except as provided in the Certificate of Designation or required by law. Each share is convertible at the holder’s option into AIBotics common stock under the formula set forth in the Certificate of Designation. The initial conversion price will equal the closing price of AIBotics common stock on its principal market on the trading day immediately preceding the transaction closing, subject to specified adjustments. Conversion is subject to certain beneficial-ownership limitations, subject to the notice and waiver provisions described in the Certificate of Designation.

AIBotics may, in its sole discretion, advance up to $2.0 million to Empulser before closing for expenditures under an approved budget. Any advances will be structured as loans secured by a first-priority security interest in all of Empulser’s assets and will be subject to the promissory note and related security documents to be negotiated.

Closing is subject to customary and transaction-specific conditions, including the transfer of 100% of Empulser’s membership interests, compliance with the parties’ covenants and representations, delivery by Empulser of audited financial statements for the periods required by Regulation S-X prepared in accordance with U.S. GAAP, and AIBotics being current in its SEC and/or OTC Markets filing obligations and labeled “Current” on OTC Markets. The Exchange Agreement provides for termination in specified circumstances if the transaction has not closed within 90 days after October 2, 2026 or if applicable closing conditions have not been satisfied or waived by January 2, 2027. There can be no assurance that the transaction will close.

As disclosed in the Form 8-K, Tsang is to provide consulting and advisory services regarding AIBotics’ existing business for 90 days or until a chief executive officer agreement becomes effective. Subject to applicable law, a satisfactory background and eligibility review, approval by AIBotics’ Board of Directors in the exercise of its fiduciary duties, and execution of a satisfactory CEO agreement, AIBotics intends to appoint Tsang as Chief Executive Officer and a director effective upon closing of the Empulser acquisition.

The foregoing is a summary of selected transaction terms. Additional information regarding the Exchange Agreement, the Series C Preferred Stock, the closing conditions and the proposed transaction is contained in AIBotics’ Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission, including the Exchange Agreement filed as Exhibit 10.1. The full agreement and filed disclosure should be reviewed for a complete description of the transaction.

Management Commentary

Ben Kaplan, Chief Executive Officer of AIBotics, said, “This is an important step in the evolution of AIBotics. Patrick brings a rare combination of global capital-markets experience, public-company transaction expertise, technology investing, corporate development and international relationships — and he has built Empulser around technologies that fit directly into where we believe AI and autonomous systems are heading. The definitive agreement gives us a potential foundation for building a much broader defense and dual-use technology platform. Patrick’s experience identifying emerging opportunities, attracting capital, developing strategic relationships and navigating public markets can be extremely valuable as we move into this next phase.”

Patrick Tsang said, “This transaction marks an important new chapter for Empulser. We believe the opportunity in autonomous systems is much broader than building another drone or robot. The real challenge is enabling intelligent machines to operate for longer, with greater resilience and less human intervention. Empulser is being built around that challenge — combining wireless power, autonomous systems and enabling technologies to increase the persistence and effectiveness of unmanned platforms. Working with Ben and the AIBotics team gives us a public-market platform from which to develop the technology, attract world-class partners and capital, and build a significant U.S. defense and dual-use technology company.”

During the pre-closing period, Tsang’s advisory role is expected to include strategic growth, capital formation, public-market strategy, corporate development, international partnerships and the evaluation of complementary emerging technologies and acquisition opportunities. As disclosed in the Form 8-K, following the closing of the acquisition of Empulser, AIBotics also intends, subject to the conditions described in the Exchange Agreement, to appoint Tsang as Chief Executive Officer and a director. The Company expects to provide additional updates as the Empulser transaction progresses and as material operating milestones are achieved.

About AIBotics

AIBotics, Inc. is a global technology company building a platform around AI-enabled robotics, autonomous systems and intelligent automation. The Company focuses on applying advanced technologies to real-world environments through strategic partnerships, technology development and international market relationships. AIBotics seeks to identify, develop, implement and scale solutions that improve how machines operate, automate business processes and extend the practical application of artificial intelligence into the physical world. Through a scalable, partnership-driven model, AIBotics is building a diversified robotics and autonomous-systems platform designed to support commercial, industrial and other mission-driven applications across global markets. For more information on AIBotics, visit www.aibotics.ai

About Empulser Enterprises LLC

Empulser Enterprises LLC is a U.S.-focused defense and dual-use technology company developing a platform around wireless power, autonomous systems, unmanned technologies and supporting infrastructure. Empulser’s development strategy is focused on technologies intended to improve the endurance, deployment and coordination of autonomous platforms across defense, government, critical-infrastructure and commercial applications. Empulser’s products and technologies are in development, and future milestones are subject to successful engineering, testing, validation, certification, funding and commercialization. For more information on Empulser, visit www.empulser.com.

About Patrick Tsang

Patrick Tsang is an international investor and entrepreneur and Chairman of Tsang Group, a fourth-generation single family office with interests across technology, real estate and natural resources. He is the Founder and Chief Executive Officer of Empulser Enterprises LLC, a U.S.-focused defense and dual-use technology company developing technologies around wireless power, autonomous systems and unmanned platforms.

Over more than two decades, Tsang has worked across international investment, capital formation, mergers and acquisitions, corporate development and emerging technology, building relationships across Asia, Europe, the Middle East and North America. Through his leadership, he was an early-stage investor and strategic advisor to Pulse Evolution, helping guide its journey through the FaceBank/fuboTV transaction to fuboTV’s listing on the New York Stock Exchange during the Covid period. SEC filings subsequently referenced an approximately 300-times return in two years on the investment based on fuboTV’s late-2020 share price.

Tsang is a qualified solicitor in England and Wales and Hong Kong and attended Harvard Business School’s Owner/President Management (OPM) program. He is the author of The Global Citizen and has been actively involved in philanthropy and international leadership throughout his career, including through the Duke of Edinburgh’s World Fellowship, Rotary International and YPO. He was recognized as China Economic Person of the Year during the China Economic Development Forum in 2014.

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of applicable securities laws. Forward-looking statements include, among other things, statements regarding the proposed acquisition of Empulser; the anticipated structure, timing, closing and benefits of the transaction; the issuance, earning and conversion of Series C Preferred Stock and potential dilution associated with conversion; the achievement and verification of earn-out milestones; any discretionary pre-closing loans by AIBotics to Empulser; the contemplated management transition involving Patrick Tsang; AIBotics’ and Empulser’s business strategies; technology development, testing, validation, certification and commercialization; intellectual-property development; financing and capital formation; strategic partnerships; government, defense and commercial opportunities; potential customers, contracts and revenue; future acquisitions; and the Company’s broader strategy in AI, robotics, autonomous systems and defense and dual-use technology. Forward-looking statements are based on current expectations, assumptions and estimates and are subject to risks and uncertainties that could cause actual results to differ materially. These risks include, among others, the possibility that the transaction may not close on the anticipated terms or timing, or at all; failure to satisfy or waive closing conditions, including delivery of required audited financial statements and maintenance of required filing status; termination following due diligence, an uncured material breach or a material adverse change; AIBotics’ decision not to provide discretionary pre-closing financing or the parties’ failure to execute satisfactory loan and security documents; failure to achieve or substantiate earn-out milestones; setoff or cancellation of earn-out consideration; dilution associated with conversion of preferred stock; failure to satisfy the conditions to Patrick Tsang’s proposed appointment as Chief Executive Officer and a director; integration risks; development and engineering risks; testing, certification and regulatory requirements; protection of intellectual property; competition; dependence on key personnel and strategic relationships; customer adoption; government procurement processes; and the Company’s ability to execute its business plan. Readers should review AIBotics’ filings with the U.S. Securities and Exchange Commission, including the Current Report on Form 8-K relating to the Exchange Agreement, for additional information concerning risks and uncertainties. Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to update them except as required by law.

Media and Investor Relations

David Kugelman
Atlanta Capital Partners, LLC
(404) 856-9157 Office
(404) 281-8556 Mobile and WhatsApp
dk@atlcp.com

• An alliance agreement was signed with PDVSA, Lindsayca and Fulcrum LNG, Inc. to restore energy infrastructure for gas production
• An MOU with New Stratus Energy Inc. was also recently signed to support the future development of in-country oil and gas resources

CARACAS, Venezuela, Oct. 05, 2026 (GLOBE NEWSWIRE) — Baker Hughes (NASDAQ: BKR), an energy technology company, Monday announced the signing of two strategic agreements to accelerate the revitalization of Venezuela’s energy infrastructure across the natural gas value chain and expansion of the country’s energy production.

In Caracas, the company signed a strategic alliance agreement with PDVSA, Lindsayca and Fulcrum LNG, Inc. to revitalize and expand the country’s natural gas infrastructure. Baker Hughes also recently signed a separate Memorandum of Understanding (MOU) with New Stratus Energy Inc. to support the development of future oil and gas prospects.

Together, these agreements establish an enterprise deal framework that can connect upstream resource development, midstream infrastructure, gas monetization, and LNG commercialization. This creates a pathway to unlock Venezuela’s significant natural gas potential.

“A central objective of these partnerships is the development of an integrated gas value chain capable of transforming Venezuela’s substantial natural gas resources into reliable domestic supply and future export opportunities, including the potential to export the first LNG molecules produced in Venezuela,” said Lorenzo Simonelli, chairman and CEO of Baker Hughes. “Venezuela holds tremendous potential to become a significant contributor to the evolving global energy landscape, and these agreements are designed to bring world-class resource opportunities, project development, energy infrastructure & technologies, and financing expertise together to realize this.”

“This strategic alliance with PDVSA is a historic opportunity to maximize the use and value of Venezuela’s natural gas resources, and it reflects the capabilities and expertise of Fulcrum, Lindsayca and Baker Hughes in developing fully integrated gas value chains, from upstream production to end markets,” said Jesus Bronchalo, CEO of Fulcrum LNG, Inc.

“In the near term, we will work closely with PDVSA to identify and execute the infrastructure developments and upgrades needed to meet its internal gas requirements, while pursuing opportunities to supply natural gas to the domestic market to support reliable power generation for Venezuela and its people. Over the medium and long term, we will evaluate the development and financing of new open-access midstream and LNG infrastructure that gives PDVSA and other upstream operators solutions to monetize their gas, positioning Venezuela to become a key player in the global gas and LNG industry and helping meet growing world energy demand,” Bronchalo said.

About the agreements

Under the alliance with PDVSA, Lindsayca and Fulcrum, the companies will combine Baker Hughes’ broad portfolio of industrialized energy solutions for oil and gas field development, gas infrastructure and LNG solutions, Lindsayca’s engineering, procurement, construction, and operational capabilities, and Fulcrum’s midstream and LNG project development, financing and market access. The collaboration will focus on developing project specific agreements, advancing critical infrastructure required to process, transport, commercialize, and export natural gas, for the first time in the history of Venezuela.

The alliance is a cooperation framework. Any specific project will be subject to separate definitive agreements, each party’s internal approvals, and applicable U.S. sanctions and export control requirements, including authorizations issued by the U.S. Department of the Treasury’s Office of Foreign Assets Control (OFAC).

Through the MOU with New Stratus Energy, Baker Hughes will support the development of future oil and gas prospects. The partnership will leverage Baker Hughes’ integrated portfolio of subsurface, drilling, production, processing, digital, emissions abatement, power generation, oil and gas monetization, and liquefied natural gas (LNG) technologies to maximize resource recovery opportunities and accelerate future project developments.

Baker Hughes has supported Venezuela’s energy sector for more than 60 years. Its installed base in country includes more than 1,200 oil production systems, the largest artificial lift footprint, significant flexible pipe infrastructure, and approximately 240 turbomachinery units across 23 sites.

About Baker Hughes
Baker Hughes (NASDAQ: BKR) is an energy technology company that provides solutions to energy and industrial customers worldwide. Built on a century of experience and conducting business in over 120 countries, our innovative technologies and services are taking energy forward – making it safer, cleaner and more efficient for people and the planet. Visit us at bakerhughes.com.

About Lindsayca Inc.

Lindsayca Inc. is a U.S. company headquartered in Houston, specializing in engineering, procurement, modular fabrication, construction, commissioning, and operation of energy infrastructure. Through Lindsay C.A., established in Venezuela in 1986, it brings four decades of experience developing gas, oil, and power generation projects in the country. Its track record combines international project execution capabilities with knowledge of Venezuela’s operating environment, specialized talent, and local engineering and fabrication resources. In alliance with PDVSA, Baker Hughes, and Fulcrum LNG, Inc., Lindsayca contributes this experience to transform Venezuela’s natural gas potential into productive infrastructure, restore power generation capacity, and strengthen the domestic energy supply. Its participation is focused on developing an integrated value chain that culminates in the production and export of liquefied natural gas (LNG), helps position Venezuela in international markets, and creates jobs, opportunities for domestic suppliers, and development for its communities.

About Fulcrum LNG, Inc.

Fulcrum LNG, Inc. is a U.S.-based independent developer of midstream natural gas and liquefied natural gas (LNG) infrastructure in international markets. Together with its world-class consortium partners, Fulcrum applies the same flexible business model used to develop gas infrastructure on the U.S. Gulf Coast. Fulcrum develops, finances, and operates shared, open-access midstream gas infrastructure, including LNG facilities, with private capital and independently of upstream producers. This approach removes the infrastructure financing burden from host governments and upstream operators, provides alternative gas monetization solutions and greater optionality, and brings more gas to domestic and export markets. Fulcrum has a broad portfolio of opportunities, primarily in Latin America and the Atlantic Basin.

For more information, please contact:

Media Relations
Adrienne M. Lynch
+1 713-906-8407
Adrienne.lynch@bakerhughes.com 

Investor Relations
Chase Mulvehill
+1 346-297-2561
investor.relations@bakerhughes.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/de053a70-43d9-472c-81c7-6721adabfb3d

Agreement with EU-based manufacturer expands TurboGen’s defense and civilian markets and features an initial five-year term with automatic renewals to support ongoing commercial production

PETAH TIKVA, Israel, Oct. 05, 2026 (GLOBE NEWSWIRE) — TurboGen Ltd. (NASDAQ:TRBG) (TASE:TURB) (“TurboGen” or the “Company”), a developer of combined heat and power systems based on multifuel microturbines, today announces it has entered into a long-term agreement (“LTA”) with an engineering and manufacturing provider for the serial development and production of the Company’s proprietary 20kW systems. 

“This milestone collaboration marks the transition from prototype development to serial production with a tier-one, EU-based global design and manufacturer. Upon completion of the development phase, we anticipate readiness for commercialization of our compact 20kW systems.” stated Yaron Gilboa, TurboGen’s Chief Executive Officer. “This LTA also aims to support product sales for defense as well as civilian projects and sales. This LTA further demonstrates TurboGen’s dedication toward rapid advancement into serial production and revenue generation.”

The initial period of the LTA will be five years, with automatic annual renewals designed to support ongoing commercial production and demand.

About TurboGen

Founded in response to technologically address the threat of climate change and the lack of grid capacity, TurboGen Ltd. (NASDAQ:TRBG) (TASE:TURB) develops combined heat and power systems based on multifuel microturbines. These microturbines are used for local electricity, energy, and heat production. To learn more, please visit: https://turbogenchp.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, TurboGen is using forward looking statements in this press release when it discusses: its transition from prototype development to serial production; commercialization of its compact 20kW systems; and its dedication towards rapid advancement into serial production and revenue generation. Because such statements deal with future events and are based on TurboGen’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of TurboGen could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (the “SEC”) on March 12, 2026, as amended, which is available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

IR and Communications Contact:

IR@turbogenchp.com

Company Expects to Realize Approximately $600,000 in Annualized Cost Savings

SAN JOSE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced that it has completed the relocation of its manufacturing facility from Mountain View, California to a new facility in San Jose, California.

“We are pleased to announce the successful relocation of our manufacturing facility. This was a key component of our plan to reduce expenses and improve profitability,” said Patrick Mercer, President and CEO of Iridex. “This relocation is expected to improve operational efficiency while providing the infrastructure required to support the business we are building for the future.”

The completed relocation is set to generate approximately $0.6 million in annualized cost savings, consistent with the expectations outlined previously. The Company anticipates further savings opportunities as the transition is fully integrated into its operations.

About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, which include capital equipment and consumable probes for the ophthalmology market. The Company’s proprietary MicroPulse^® technology delivers the therapeutic benefits of laser treatment while minimizing tissue damage, offering a safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.

Iridex, the Iridex logo, MicroPulse, the MicroPulse Logo, Iridex PASCAL, IQ 532, IQ 577, OcuLight, TxCell, Cyclo G6, MicroPulse P3, G-Probe, G-Probe Illuminate and EndoProbe are registered trademarks of Iridex Corporation, Inc. in the United States, Europe, and other jurisdictions.

Investor Relations Contact
Philip Taylor
Gilmartin Group
investors@iridex.com

TORONTO and GERMANTOWN, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) — Sernova Biotherapeutics Inc. (“Sernova”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO) and Seraxis Holdings, Inc. (“Seraxis”) today announced the closing of the previously announced targeted US$10 million non-brokered convertible note financing in connection with their proposed merger (the “Merger”) to form BetaNova Biotherapeutics, Inc. (“BetaNova”).

The US$11.2 million financing into Seraxis includes participation from insiders, Dr. Steven Sangha / Arlo Investments, Sernova management; Jonathan Rigby CEO, James Parsons CFO, Marylyn Rigby CCO, and David Burke VP IR, as well as Seraxis management; Will Rust Ph.D. CEO, and Carole Welsch Ph.D. COO. Existing shareholders and new investors also participated in the financing.

Proceeds from the financing are expected to support:

• cGMP manufacturing of SR-02, allogeneic stem cell-derived pancreatic islet cells;
• Enrollment of patients with T1D in Q4 for Phase 1 / 2 clinical trial;
• First patient dosing of SR-02 in Phase 1/2 clinical trial in Q1 2027 under an FDA-cleared IND with initial clinical data anticipated in H1 2027;
• Nasdaq listing readiness targeted for Q1 2027, subject to satisfaction of applicable listing requirements and approvals; and
• Advancement of SR-03, the next-generation gene-edited pancreatic islet cell program targeting immune evasion, toward an IND submission in the second half of 2027.

“This financing puts capital directly behind the milestones we have outlined for BetaNova as we passionately advance towards a potential functional cure for people living with T1D,” said Jonathan Rigby, President and Chief Executive Officer of Sernova. “With the financing now closed, we believe BetaNova is positioned to successfully compete with other companies in the T1D cell therapy space by entering the clinic in the near term. Our focus is on execution, while deploying capital efficiently.”

“Closing the financing provides the resources to advance the manufacturing activities required to support SR-02 islet cells and prepare for initiation of the Phase 1/2 clinical trial,” said Will Rust, Ph.D., President and Chief Executive Officer of Seraxis. “As we work toward completion of the Merger, our teams are aligned around a shared mission, a clear development strategy and a defined set of milestones for 2026 and 2027.”

Proposed Merger

Sernova and Seraxis entered into a definitive merger agreement on September 7, 2026, to form BetaNova, combining Seraxis’ stem cell-derived pancreatic islet programs and cGMP manufacturing capabilities with Sernova’s Cell Pouch Bio-hybrid Organ. The completion of the Merger is subject to required approvals and customary closing conditions. Upon completion, each of Sernova and Seraxis shareholders are expected to collectively own approximately 50% of BetaNova on a non-diluted basis.

Noble Capital Markets, Inc. is acting as exclusive financial advisor to Sernova in connection with the proposed Merger.

About the Financing

The US$11.2 million financing consists of convertible notes and common stock purchase warrants of Seraxis issued on a non-brokered basis. Upon completion of the Merger, the notes are expected to automatically convert into common stock of BetaNova.

ABOUT BETANOVA BIOTHERAPEUTICS, INC.

BetaNova Biotherapeutics, Inc. is the proposed combined company of Sernova Biotherapeutics Inc. and Seraxis Holdings, Inc. Subject to completion of the proposed transaction, BetaNova will be a clinical-stage regenerative medicine company focused on advancing cell-replacement therapies for type 1 diabetes. BetaNova will combine Seraxis’ stem cell-derived islet cell and cGMP manufacturing platform with Sernova’s Cell Pouch Bio-hybrid Organ.

ABOUT SERNOVA BIOTHERAPEUTICS INC.

Sernova Biotherapeutics Inc. is a clinical-stage company developing a regenerative medicine solution for T1D that combines its Cell Pouch implantation device, deep clinical experience in the engraftment of functional pancreatic cells, and therapeutic cells to create a Bio-hybrid, functional surrogate endocrine organ.

ABOUT SERAXIS HOLDINGS, INC.

Seraxis Holdings, Inc. develops stem cell-derived pancreatic islets under cGMP manufacturing processes. Seraxis’ mission is to demonstrate safety and potency of its islets in T1D patients without immune suppression therapy. To accomplish this goal, its lead allogeneic product, SR-02, is paired with an immune tolerizing strategy. Seraxis’ follow-on product SR-03 adds gene edits to SR-02 that increase compatibility with the host and potentially enhance long-term engraftment without immune suppression.

For Further Information Contact:

Investor Relations
David Burke
Vice President, Investor Relations
Sernova Biotherapeutics Inc.
(917) 751-5713
David.Burke@sernova.com

Media
Gloria Gasaatura
VP, LifeSci Communications
SernovaPR@lifescicomms.com

Forward-Looking Information

This news release contains “forward-looking statements” and “forward-looking information” within the meaning of applicable securities laws. Particularly statements and information regarding the proposed Merger of Sernova and Seraxis, the anticipated formation of BetaNova, the anticipated use of proceeds from the financing, manufacturing of SR-02, the timing of patient dosing and availability of clinical data, development of SR-03, and the anticipated completion of the Merger. In some cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “budget”, “scheduled”, “estimates”, “outlook”, “forecasts”, “projection”, “prospects”, “strategy”, “intends”, “anticipates”, “does not anticipate”, “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “will”, “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking information.

Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events or circumstances. These statements include, without limitation, statements regarding the receipt, in a timely manner, of shareholder, court and regulatory approvals in respect of the Merger, the expected closing date for the Merger and BetaNova’s leadership, business prospects and operations following closing of the Merger and the anticipated use of proceeds and results thereof from the non-brokered financing. Undue reliance should not be placed on forward-looking information. The forward-looking information in this press release is based on our opinions, estimates and assumptions in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we currently believe are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. Further, forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to risks relating to regulatory interactions, manufacturing, patient recruitment, clinical development, financing requirements, completion of the proposed Merger and satisfaction of applicable Nasdaq listing requirements.

Additional information about the risks and uncertainties of Sernova’s business and material risk factors or assumptions on which information contained in forward-looking information is based is provided in Sernova’s disclosure materials, including Sernova’s most recently filed news release, annual information form and any subsequently-filed interim management’s discussion and analysis, which are available under our profile on SEDAR+ at www.sedarplus.ca. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this press release represents our expectations as of the date of this news release and is subject to change after such date. Sernova disclaims any intention or obligation or undertaking to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities law.

Partnership intended to establish a Texas-based manufacturing pathway for pharmaceutical-grade ibogaine as TIRC advances its planned U.S. development program

HIGHLIGHTS

• Texas Ibogaine Research Corporation (“TIRC”), the wholly-owned Texas subsidiary of Psyence BioMed, enters manufacturing partnership with Benuvia Operations, LLC for the planned U.S. manufacture of pharmaceutical-grade ibogaine active pharmaceutical ingredient (“API”)
• Benuvia operates an 83,000-square-foot, DEA-registered controlled-substance manufacturing facility in Round Rock, Texas, with capabilities spanning development through commercial-scale production
• Partnership is intended to connect TIRC’s planned exclusive U.S. access to PsyLabs’ pharmaceutical-grade ibogaine under TIRC’s previously announced binding term sheet with PsyLabs, with U.S.-based controlled-substance manufacturing capabilities
• The partnership represents another step in Psyence BioMed’s strategy to build an integrated U.S. supply, manufacturing and regulatory development platform for ibogaine through TIRC

NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today announced that its wholly-owned Texas subsidiary, Texas Ibogaine Research Corporation (“TIRC”), has entered into a manufacturing services agreement with Benuvia Operations, LLC (“Benuvia”) of Round Rock, Texas, establishing a manufacturing partnership for the planned U.S. manufacture of pharmaceutical-grade ibogaine active pharmaceutical ingredient (“API”) under current Good Manufacturing Practice (“cGMP”) standards.

The manufacturing partnership builds upon TIRC’s previously announced binding term sheet with Psyence Labs Ltd. (“PsyLabs”), a significant shareholder of Psyence BioMed and in which Psyence BioMed holds an ownership interest, for an exclusive U.S. license, supply and wholesale distribution arrangement covering PsyLabs’ pharmaceutical-grade ibogaine. The term sheet is to be superseded by a definitive agreement, which the parties have agreed to conclude on or before November 30, 2026. PsyLabs’ material is supported by a regulatory-readiness package that includes GMP-compliant production, an Investigator’s Brochure and certificates of analysis.

Benuvia operates an approximately 83,000-square-foot pharmaceutical manufacturing facility in Round Rock, Texas, registered with the U.S. Drug Enforcement Administration (“DEA”), with capabilities spanning controlled-substance API development and manufacturing, analytical development, stability programs and regulatory support. According to Benuvia, it currently holds approximately half of the U.S. aggregate production quota for ibogaine, providing an established foundation for potential domestic production. Applications for the import permit and procurement quota required for the planned production are being advanced with the DEA by Benuvia. Because Benuvia’s commercial-scale manufacturing infrastructure is already in place, the Company believes that the timing and scale of any U.S. ibogaine production will be governed primarily by applicable DEA quotas, controlled-substance import requirements and other regulatory authorizations.

“Benuvia brings a DEA-registered U.S. facility with the quota, systems and track record required to manufacture controlled substances to pharmaceutical standards,” said Jody Aufrichtig, Chief Executive Officer of Psyence BioMed and TIRC. “Combined with our planned licensed supply, we believe this has the potential to create an end-to-end pathway from pharmaceutical-grade source material through U.S.-based manufacturing.”

“Benuvia brings more than 10 years of experience in the development and commercial manufacturing of DEA Schedule I–V controlled substances to rigorous pharmaceutical standards,” said Terry Novak, Chief Executive Officer of Benuvia. “Our Round Rock facility was purpose-built for controlled-substance manufacturing and provides the infrastructure, regulatory capabilities, and commercial-scale capacity required for complex programs like ibogaine. While ibogaine has been discussed for decades, pharmaceutical-grade manufacturing capacity in the United States has remained extremely limited. Through our partnership with TIRC and Psyence BioMed, we believe we have an opportunity to change that — manufacturing ibogaine in America, to exacting specifications and at the scale this program will require if and as DEA quota expands. We have the experience, the facility, and the team in place. We are ready to begin.”

“For a regulated ibogaine development program, manufacturing is inseparable from the regulatory strategy,” said Dr. John Thorne, Project Lead, TIRC. “Establishing a U.S.-based manufacturing pathway is intended to strengthen chain-of-custody controls, batch consistency and the chemistry, manufacturing and controls work required to support future regulatory submissions. We believe Benuvia’s capabilities give us an experienced U.S. manufacturing platform on which to build that work.”

Psyence BioMed views this manufacturing partnership as more than a manufacturing milestone; it is part of a broader effort to advance the clinical and regulatory work required to develop potential ibogaine-based therapies for patients facing significant unmet needs, including opioid use disorder, other substance use disorders and mental health conditions affecting veterans.

The Company believes that the combination of pharmaceutical-grade supply at source and Texas-based cGMP manufacturing would position TIRC to support regulated research and clinical programs if and when applicable quotas are expanded. If compliant U.S. production capacity is established, the Company believes it would be better positioned to support the research and clinical development programs that could ultimately underpin future regulatory approvals and patient access.

ABOUT PSYENCE BIOMED

Psyence Biomedical Ltd. (Nasdaq: PBM) is a Nasdaq-listed company with its wholly-owned subsidiary, Texas Ibogaine Research Corporation, headquartered in Texas. It is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in neuroplastogen-based therapeutics and the manufacture of pharmaceutical-grade drug candidates. It is the first life sciences biotechnology company focused on developing nature-derived, non-synthetic psilocybin and ibogaine-based neuroplastogen medicine to be listed on Nasdaq. The Company is dedicated to addressing unmet mental health needs and is committed to an evidence-based approach to developing safe, effective and FDA-approved nature-derived neuroplastogen treatments across a range of mental health disorders.

ABOUT PSYLABS

PsyLabs is a neuroplastogen active pharmaceutical ingredient development company, federally licensed in its operating jurisdiction to cultivate, extract and export psilocybin mushrooms and other neuroplastogen compounds, including psilocybin, psilocin, mescaline, ibogaine and dimethyltryptamine, to lawful medical and research markets. PsyLabs operates from an ISO 22000 and GMP-compliant facility, with a focus on natural compound purification, regulatory support and global distribution. www.psylabs.life

CONTACTS

Psyence Biomedical Ltd. · ir@psyencebiomed.com · media@psyencebiomed.com · info@psyencebiomed.com · +1 416-477-1708

Investor contact: Michael Kydd, Investor Relations Advisor — michael@psyencebiomed.com

FORWARD-LOOKING STATEMENTS

This communication contains “forward-looking statements” within the meaning of applicable securities laws, including the U.S. Private Securities Litigation Reform Act of 1995. These include statements regarding the manufacturing partnership with Benuvia and its intended scope, benefits and timing; the planned U.S. manufacture of pharmaceutical-grade ibogaine API; the timing and outcome of import permit, procurement quota and other DEA applications and authorizations; the ability to manufacture material to specification and on schedule; the potential for future increases in DEA quotas; the conclusion of a definitive agreement with PsyLabs in accordance with the previously announced binding term sheet and the rights to be granted to TIRC under it; the Company’s strategy to build an integrated U.S. supply, manufacturing and regulatory development platform for ibogaine through TIRC; the planned U.S. development program and any future clinical, regulatory or commercial activities; and the Company’s ability to support regulated research and clinical programs. Forward-looking statements may be identified by words such as “will,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates” and similar expressions.

These statements are based on assumptions regarding government policy, continued interest in regulated neuroplastogen research, the availability of lawful development pathways, and the Company’s ability to maintain licenses, permits, supply arrangements and third-party relationships. These assumptions may prove incorrect. Risks and uncertainties that could cause actual results to differ materially include that import permit, quota, registration or other regulatory approvals are delayed, limited or refused; that the arrangements with Benuvia are terminated, are not performed or do not proceed as intended; reliance on a single manufacturing partner and the consequences of any interruption; manufacturing, analytical or supply-chain failures; that a definitive agreement with PsyLabs is not concluded by November 30, 2026, or at all, or is concluded on terms that differ from the term sheet; dependence on PsyLabs, a related party, as exclusive licensor and supplier; changes in law, regulation or enforcement priorities in the United States or elsewhere; the continuing status of ibogaine as a controlled substance; clinical, regulatory and approval risks; financing risk; and the Company’s ability to maintain compliance with Nasdaq continued listing standards. This list is not exhaustive. These risks should be considered together with the risk factors described in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the fiscal year ended March 31, 2026 and in the Company’s other filings with the U.S. Securities and Exchange Commission. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Readers should not place undue reliance on forward-looking statements, which speak only as of the date made. Except as required by law, the Company undertakes no obligation to update such statements.

The Company makes no medical, treatment or health benefit claims regarding its proposed products. The U.S. Food and Drug Administration, Health Canada and other regulatory authorities have not approved ibogaine or the Company’s other neuroplastogen compounds for therapeutic use, and their safety and efficacy have not been established through authorized clinical research. Rigorous scientific research and clinical trials are required. Information in this communication regarding Benuvia, including its facility, capabilities, DEA registration and quota allocations, has been provided by Benuvia and has not been independently verified by the Company. Any references to ibogaine stock, inventory or doses are the Company’s best estimates only. References to GMP-compliant mean production in a facility designed, operated and controlled in accordance with applicable Good Manufacturing Practice standards, and do not themselves constitute a representation of formal certification or approval by any regulatory authority unless expressly stated. References to a planned clinical trial describe an activity under evaluation only; no trial has been commenced, and no regulatory application in respect of it has been filed or accepted.

This communication is not an offer to sell or a solicitation of an offer to buy any securities.

Alector grants Genentech exclusive rights to develop and commercialize AL050, an investigational GCase Enzyme Replacement Therapy (ERT) enabled by Alector Brain Carrier (ABC), Alector’s proprietary blood-brain barrier delivery platform

Alector to receive $100 million upfront payment, with potential for up to $1.17 billion in additional milestone payments, as well as tiered royalties on net sales

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it has entered into an exclusive global licensing agreement with Genentech, a member of the Roche Group, granting Genentech worldwide rights to develop and commercialize Alector’s AL050 program, its brain-penetrant engineered glucocerebrosidase (GCase) ERT.

AL050 is designed to address GCase deficiency, a driver of neurodegeneration in Parkinson’s Disease that is most pronounced in – but not limited to – carriers of GBA1 mutations. It combines an Alector-engineered GCase, optimized for greater enzymatic activity and a longer half-life, with Alector’s ABC, which is designed to transport therapeutics across the blood-brain barrier. Delivered into the brain, the enzyme is intended to break down glucosylsphingosine and glucosylceramide, lipids that accumulate in neurons and other brain cells upon GCase deficiency and contribute to neurodegeneration, with the aim of reducing cellular dysfunction and slowing disease progression.

“Deficient GCase activity is increasingly recognized as a contributor to Parkinson’s Disease, and there is still no approved therapy that addresses the underlying enzyme deficiency,” said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. “The challenge in treating GCase deficiency is twofold: engineering an enzyme with optimal activity and durability and successfully delivering it to the brain. AL050 addresses this by pairing an engineered GCase enzyme with our proprietary Alector Brain Carrier technology designed to cross the blood-brain barrier. Genentech’s long-standing commitment to Parkinson’s Disease makes them an ideal partner as this program moves toward the clinic”.

“Parkinson’s Disease is one of the fastest-growing neurological conditions worldwide,” said Boris L. Zaïtra, Head of Roche Corporate Business Development. “By partnering with companies such as Alector we aim to delay or halt the progression of Parkinson’s so patients maintain and prolong their independence.”

Under the terms of the agreement, Alector will receive an upfront payment of $100 million and is also eligible to receive additional payments of up to $1.17 billion upon the achievement of development, regulatory, and commercial milestones. Alector is also eligible for tiered royalties on net sales. Under the collaboration, Genentech will be responsible for development, regulatory, manufacturing, and commercialization across all indications.  Alector retains ownership of ABC and full rights to apply the platform across its wholly owned pipeline.  

“This partnership extends our cash runway into 2029, providing resources to advance our fully active, subcutaneously delivered, brain-enabled anti-Aβ antibody to multi-cohort clinical data in Alzheimer’s patients, and move our subcutaneously delivered, brain-enabled Tau siRNA and alpha- synuclein siRNA programs through IND-enabling studies and to IND filings,” said Dr. Rosenthal.

Alector R&D Webinar on Wholly Owned Pipeline

Alector will host a scientific webinar on Tuesday, October 13^th, 2026, at 8:00 a.m. PT, focused on AL137, its brain-enabled anti-Aβ antibody; AL164, its tau siRNA program; and AL062, its alpha-synuclein siRNA program. Registration and webcast information will be available on the Events and Presentations page of the Alector corporate website.

About Alector

Alector is a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as Alzheimer’s disease and Parkinson’s disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being applied to its preclinical and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding our business plans, business strategy, product candidates, research and preclinical pipeline, blood-brain barrier technology platform, planned and ongoing preclinical studies, planned clinical trials, expected milestones, expectations of our collaborations, and financial and cash guidance. Such statements are subject to numerous risks and uncertainties, including but not limited to risks and uncertainties as set forth in Alector’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, with the Securities and Exchange Commission (SEC), as well as the other documents Alector files from time to time with the SEC. These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alector’s forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law.

Alector Contacts

Argot Partners (media)
David Rosen
646-461-6387
alector@argotpartners.com

Argot Partners (investors)
Laura Perry
alector@argotpartners.com

—Supports BioCryst’s evolution toward a more disciplined R&D model centered on external innovation—

RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the formation of a Scientific Advisory Board (SAB) comprising seven accomplished scientific and industry leaders with deep expertise across rare disease research and drug development. The SAB will provide independent scientific and strategic guidance as the Company advances its research and development strategy and builds a high value novel drug pipeline.

“The formation of BioCryst’s Scientific Advisory Board marks an important step in the evolution of our new R&D model,” said Dr. Sandeep Menon, BioCryst’s Chief Research and Development Officer. “External innovation is increasingly central to how we build our pipeline, and guidance from leading scientists and physicians will sharpen our thinking and strengthen the diligence behind each program we evaluate and advance. The Scientific Advisory Board will work closely with me and our Chief Scientific Officer, Dr. David Jenkins, as we shape and execute BioCryst’s R&D strategy.”

“Building on our success in developing and commercializing medicines for hereditary angioedema, we are bringing the same rigor to the next generation of BioCryst medicines,” said Charlie Gayer, Chief Executive Officer. “With the expertise of these highly experienced scientific advisors, BioCryst will be better positioned to evaluate emerging opportunities and translate their potential into meaningful benefits for patients.”

The SAB will provide strategic guidance across BioCryst’s research and development activities, including pipeline expansion, external innovation opportunities, translational science and clinical development. The board will also offer insights on regulatory strategy and help strengthen connections with leading scientific, medical and patient communities worldwide.

“Few companies have demonstrated BioCryst’s ability to translate rigorous science into rare disease medicines that reach patients, and that track record is what makes the Company’s evolution so compelling,” said Dr. Anthony Manning, Chair of the Scientific Advisory Board. “The formation of this Board is an important step for BioCryst, and it is a privilege to chair a group with this depth of experience across rare disease drug discovery, translational science and clinical development. I am confident the Company’s decisions about which science to pursue and how to advance it will benefit from the collective judgment of its members.”

Scientific Advisory Board Members:

• Anthony (Tony) Manning, PhD, Chair, is Principal at Manning Bio Worldwide, LLC, advising biotechnology companies and academic institutions following a 30-year career in pharmaceutical drug discovery and development. As Chief Scientific Officer at Momenta Pharmaceuticals (now part of Johnson & Johnson), he built a pipeline of first-in-class therapeutics for rare autoantibody-driven diseases, including nipocalimab (IMAAVY), now FDA-approved for generalized myasthenia gravis and warm autoimmune hemolytic anemia, with additional indications in development. Earlier, he led drug discovery efforts at Roche Pharmaceuticals and Biogen Idec, contributing to the approvals of Actemra and Rituxan, and to the development of litifilimab, now in Phase 3 for lupus.
   
• Dr. Christine Bulawa, PhD, received a PhD from the University of Wisconsin-Madison and completed postdoctoral studies at Massachusetts Institute of Technology (MIT). As part of her 20+ years in rare disease drug discovery, she was the first employee of FoldRx Pharmaceuticals and instrumental in the preclinical development of tafamidis, the first pharmacological treatment for transthyretin amyloidosis. As a senior leader in Pfizer’s Rare Disease Research Unit, Dr. Bulawa built a pipeline of innovative programs based on rigorously validated targets, spanning portfolio entry to clinical development, with a focus on small molecule and genetic therapies to treat degenerative neurological, neuromuscular and protein aggregation diseases. 
   
• Dr. Eric A. Hughes, MD, PhD, serves as Executive Vice President, Global Research & Development and Chief Medical Officer at Teva Pharmaceuticals. A physician-scientist who earned his MD and PhD from Yale University, Dr. Hughes brings nearly 20 years of biopharmaceutical industry experience and is helping advance Teva’s transformation into a leading innovative biopharmaceutical company, enabled by a world-class generics business.  Prior to Teva, he served in leadership roles at Vertex, Novartis and Bristol Myers Squibb.
   
• Dr. Stephanie Noviello, MD, MPH, is Chief Medical Officer at ILiAD Biotechnologies, Inc. She is a clinical development leader with extensive experience across infectious diseases, virology, immunology, rare diseases and skeletal diseases at Novartis, Motif BioSciences, Bristol-Myers Squibb and Schering-Plough Research Institute.
   
• Dr. Shashi Ramaiah, DVM, PhD, DACVP, DABT, is a board-certified Veterinary Pathologist and Toxicologist who spent 18 years at Pfizer, most recently as Vice President and Global Head of Discovery, Investigative and Translational Sciences. He is Founder and CEO of SPECCRO, a drug development advisory firm that helps biotechnology companies and investors de-risk programs and portfolios, drawing on more than 40 senior industry experts and extensive engagement with national and international scientific consortia.
   
• Dr. Art Taveras, PhD, is a seasoned biopharmaceutical executive with over 35 years of industry experience, specializing in leading R&D divisions across major public pharmaceutical corporations and biotech firms including Biogen Idec, Transform Therapeutics, X4 Pharmaceuticals, CoMET Therapeutics, ShangPharma ChemPartner, Alantos Pharmaceuticals and Schering-Plough. His strategic expertise as President, CEO, CSO and R&D Leader has advanced robust pipelines and key global R&D partnerships, culminating in over 175 patent application filings, 150 publications, 60 clinical trials, 6 regulatory agency approvals and 5 therapeutic platform technologies across commercial and clinical-stage assets for diseases in neurology, oncology, immunology, metabolism and rare disease.
   
• Dr. Ajay Yekkirala, PhD, is an experienced serial entrepreneur who co-founded Superluminal Medicines at RA Capital and built a strong investor syndicate including NVIDIA, Eli Lilly, Insight Partners, Catalio, BVF and Perceptive Advisors. As Chief Scientific Officer, he directs the AI/ML platform build and all pipeline R&D. Prior to Superluminal, Dr. Yekkirala founded Blue Therapeutics to develop non-addictive painkillers. He received his PhD from the University of Minnesota and completed postdoctoral training at Harvard Medical School. He has authored several papers published in high-impact, peer-reviewed journals and advised various committees at the NIH, including EPPIC-NET at NINDS and Medication Development Research Committee at NIDA.

About BioCryst Pharmaceuticals
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor and is advancing a pipeline of potential first-in-class or best-in-class therapeutics for rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding future results, performance, or achievements, expectations regarding BioCryst’s strategic shift to prioritize external innovation, expectations regarding pipeline development, the anticipated role and potential benefits of BioCryst’s Scientific Advisory Board, and statements related to BioCryst’s future operations, prospects and pipeline programs. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: BioCryst’s ability to successfully progress its pipeline development plans; guidance and recommendations provided by the Scientific Advisory Board may not improve BioCryst’s evaluation or advancement of potential programs or result in the anticipated benefits; the commercial viability of BioCryst’s future rare disease therapies; ongoing and future development of product candidates may take longer than expected and may not have positive results; product candidates, if approved, may not achieve market acceptance; the results of BioCryst’s partnerships with third parties may not meet BioCryst’s current expectations; and BioCryst’s ability to realize the contemplated benefits of its new R&D strategy and model and successfully evaluate and execute external opportunities. This list is not exclusive. To see a more comprehensive list of risks, please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause actual results to differ materially from those contained in BioCryst’s projections and forward-looking statements.

Contact:

Investors:
investorrelations@biocryst.com

Media:
media@biocryst.com

DV helps advertisers measure the impact of advertising in ChatGPT across the customer journey while developing brand risk and suitability pilots for conversational advertising

NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) — DoubleVerify (“DV”) (NYSE: DV), the leading software platform to verify media quality, optimize advertising performance and prove campaign outcomes, today announced the launch of attribution measurement for advertising on ChatGPT. Advertisers can now incorporate ChatGPT Ads as a touchpoint within the broader customer journey, helping them understand its contribution to outcomes and overall return on ad spend (ROAS).

DV and OpenAI are also developing a brand suitability evaluation pilot designed to enable independent partners to collaborate with OpenAI to assess and help inform brand suitability policies and guardrails in a controlled testing environment, without accessing private user conversations.

Understanding ChatGPT Ads’ Role in the Customer Journey

With this announcement, DV enables advertisers to measure ChatGPT Ads alongside their other marketing touchpoints, helping brands understand how the channel contributes to acquisition goals, conversions and overall campaign performance. By incorporating ChatGPT Ads into their attribution measurement, advertisers can evaluate its impact alongside other channels rather than viewing performance in isolation.

“Advertisers want to understand not just whether a new channel is performing, but the business impact it’s actually driving,” said Mark Zagorski, CEO of DV. “By bringing ChatGPT Ads into DV’s attribution measurement through DV Rockerbox™, marketers can connect engagement on ChatGPT to outcomes and return on ad spend, giving them a clearer view of its role across the customer journey.”

Early results demonstrate the value of this approach. Weight Watchers added ChatGPT Ads as a new source of member acquisition and used DV Rockerbox to independently measure its performance. ChatGPT’s attributed cost per acquisition was 15.3% below Weight Watchers’ established benchmark during the measured period, providing an early signal of the channel’s potential as the company evaluates increased investment.

“As new advertising channels emerge, we need to understand how they contribute to the broader customer journey,” said Jake Dmochowski, VP of Growth, Weight Watchers. “DV Rockerbox helped us put ChatGPT Ads performance into context alongside our existing investments, giving us an encouraging early signal and greater clarity as we evaluate how to scale.”

Advancing Brand Suitability for ChatGPT Ads

As part of this announcement, DV and OpenAI are developing a brand risk and suitability evaluation pilot designed to assess conversational context at scale, helping advertisers determine whether ad placements align with their brand suitability preferences. The goal is to give advertisers greater transparency into how those policies and guardrails work while protecting conversation privacy.

“Conversational environments are fundamentally different because context is dynamic. What a user asks, how the AI responds and how the conversation evolves can all shape the environment in which an ad appears,” added Zagorski. “That requires a new approach to brand risk and suitability. As advertising on ChatGPT scales, advertisers need confidence that their brands are appearing in suitable environments, with context evaluated while user privacy is protected.”

Together, attribution and brand suitability measurement will address two fundamental advertiser needs: understanding the business impact of their investment and gaining greater confidence in the context in which their brands appear.

DV’s brand suitability and attribution capabilities are part of the DV Media AdVantage Platform (DV MAP™), the full-spectrum media effectiveness platform that combines media verification, AI-powered optimization through DV Scibids AI™ and campaign outcomes measurement with DV Rockerbox to maximize media effectiveness and return on ad spend. These capabilities help advertisers drive stronger business outcomes across channels, devices and formats.

For more information about this release, contact Sales@doubleverify.com

About DV

DoubleVerify (“DV”) (NYSE: DV) is the industry’s leading media effectiveness platform that leverages AI to drive superior outcomes for global brands. By powering media efficiency and performance, DV strengthens the online advertising ecosystem, preserving the fair value exchange between buyers and sellers of digital media. Learn more at www.doubleverify.com

Chris Harihar 
646-535-9475 
chris@crenshawcomm.com